3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Specimen Handling
5
Observation
4
Blood Specimen Collection
4
Surveys and Questionnaires
3
Drug Therapy
3
Chemoradiotherapy
3
Surgical Procedures, Operative
2
Electrocardiography
2
Echocardiography
2
Capecitabine
2
Biopsy
2
trifluridine tipiracil drug combination
1
tegafur-gimeracil-oteracil
1
somapacitan
1
olverembatinib
1
lorlatinib
1
lenvatinib
1
gallium 68 PSMA-11
1
brexucabtagene autoleucel
1
axicabtagene ciloleucel
1
Zoledronic Acid
1
Tumor Burden
1
Telemedicine
1
Tegafur
1
Stents
1
S 1 (combination)
1
Robotic Surgical Procedures
1
Rituximab
1
Radiotherapy
1
Radiography, Panoramic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Enrolling by invitation
×
Observational
×
Inosine Monophosphate
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled